ABBV vs. MRK, JNJ, PFE, BMY, IQV, MRNA, IDXX, BNTX, ILMN, and JANX
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Pfizer (PFE), Bristol-Myers Squibb (BMY), IQVIA (IQV), Moderna (MRNA), IDEXX Laboratories (IDXX), BioNTech (BNTX), Illumina (ILMN), and Janux Therapeutics (JANX). These companies are all part of the "medical" sector.
AbbVie (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.9%. Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.3%. AbbVie pays out 227.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie is clearly the better dividend stock, given its higher yield and lower payout ratio.
AbbVie received 332 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 73.06% of users gave AbbVie an outperform vote while only 66.97% of users gave Merck & Co., Inc. an outperform vote.
AbbVie has a net margin of 8.95% compared to Merck & Co., Inc.'s net margin of 3.76%. AbbVie's return on equity of 162.28% beat Merck & Co., Inc.'s return on equity.
In the previous week, AbbVie had 7 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 49 mentions for AbbVie and 42 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.86 beat AbbVie's score of 0.62 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.
AbbVie has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.
70.2% of AbbVie shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of AbbVie shares are held by company insiders. Comparatively, 0.1% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
AbbVie has higher earnings, but lower revenue than Merck & Co., Inc.. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
AbbVie presently has a consensus target price of $176.08, indicating a potential upside of 10.31%. Merck & Co., Inc. has a consensus target price of $131.33, indicating a potential upside of 0.10%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than Merck & Co., Inc..
Summary
AbbVie beats Merck & Co., Inc. on 15 of the 20 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
